中国药理学与毒理学杂志2012，Vol.26Issue(3)：411-414,4.DOI:10.3867/j.issn.1000-3002.2012.03.030
基因多态对他莫昔芬疗效影响研究进展
Progress in research about the impact of gene polymorphisms on tamoxifen therapy
摘要
Abstract
Tamoxifen has been the gold standard for endocrine treatment of breast cancer patients of estrogen receptor (ER)-positive. However, 30% -50% of the patients have been found to display tamoxifen resistance. Genetic polymorphisms of metabolizing enzymes CYP2D6, CYP2C19, and SULT1A1 were found significantly associated with anticancer effects of tamoxifen. ABC transporter gene ABCC2 and estrogen receptor gene polymorphisms were also found to play considerable roles in tamoxifen's response. Although the impact of some gene polymorphisms on the effect of tamoxifen still need to be clarified, all the pharmacogenetic informations about tamoxifen will finally be put together to provide the whole profile of the genetic basis for tamoxifen's drug resistance. Achievements in this area such as the finding of the stable relation of CYP2D6 genotypes and tamoxifen response, will help to find practical ways to improve tamoxifen therapy.关键词
他莫昔芬/多态性,单核苷酸/乳腺肿瘤Key words
tamoxifen/ polymorphism, nucleotide/ breast neoplasms分类
医药卫生引用本文复制引用
张燕青,王连生..基因多态对他莫昔芬疗效影响研究进展[J].中国药理学与毒理学杂志,2012,26(3):411-414,4.基金项目
国家自然科学基金(81072707) （81072707）
